Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotechnology company focused on therapies for liver and viral diseases, announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open.

Aligos emphasizes a science-driven approach and R&D expertise to advance a pipeline addressing high unmet medical needs, including chronic hepatitis B virus (HBV) infection. Investors and stakeholders can find more information at the company’s website or by contacting Investor Relations.

News Market Reaction – ALGS

+1.65%

2 alerts

+1.65% Session close to close

$27.79M Market Cap

0.1x Rel. Volume

In the Jul 30 session, ALGS gained 1.65%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Aligos’s prior earnings-date notices were followed by 1.67% and 8.07% 24-hour gains. That history pl...

Analysis

Aligos’s prior earnings-date notices were followed by 1.67% and 8.07% 24-hour gains. That history places this scheduling notice in a context of positive precedent, while the upcoming results remain the substantive item to watch.

Key Figures

Reporting period: 2nd quarter 2026 Results release date: August 6, 2026

2 metrics

Reporting period 2nd quarter 2026 Scheduled financial results announcement

Results release date August 6, 2026 Before the open of U.S. financial markets

Previous Earnings date Reports

2 past events · Latest: Apr 30 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	1Q26 results date	Neutral	+1.7%	Announced the date for reporting first-quarter 2026 financial results after market close.
Feb 26	4Q25 results date	Neutral	+8.1%	Announced the date for reporting fourth-quarter 2025 financial results before market open.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both prior earnings-date notices were followed by positive 24-hour reactions of 1.67% and 8.07%.

Key Terms

hbv

1 terms

hbv medical

"such as chronic hepatitis B virus (HBV) infection"

HBV stands for hepatitis B virus, a contagious virus that infects the liver and can cause both short-term illness and long-term liver damage. For investors, HBV matters because diagnostics, vaccines and treatments aimed at preventing or managing the infection can create sizable markets and regulatory milestones; think of it like a widespread problem that creates demand for tools and medicines, where successful products can materially affect a company’s revenue and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2026 financial results on Thursday, August 6, 2026, before the open of the U.S. financial markets.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com

FAQ

When will Aligos Therapeutics (NASDAQ: ALGS) report its Q2 2026 financial results?

Aligos Therapeutics will report its Q2 2026 financial results on Thursday, August 6, 2026, before U.S. markets open. According to Aligos, this timing lets investors review the company’s quarterly performance ahead of that day’s regular trading session.

What type of company is Aligos Therapeutics (ALGS) and what is its main focus?

Aligos Therapeutics is a clinical stage biopharmaceutical company focused on liver and viral diseases. According to Aligos, it uses a science-driven approach and deep R&D expertise to develop best-in-class therapies for conditions with high unmet medical needs.

Which diseases is Aligos Therapeutics (ALGS) targeting with its drug pipeline?

Aligos Therapeutics targets liver and viral diseases, including chronic hepatitis B virus (HBV) infection. According to Aligos, its purpose-built pipeline is designed to address high unmet medical needs in these areas using a science-driven research and development strategy.

How can investors get more information about Aligos Therapeutics (NASDAQ: ALGS)?

Investors can learn more about Aligos Therapeutics by visiting www.aligos.com. According to Aligos, stakeholders may also follow the company on LinkedIn or X, or contact Investor Relations via the published phone number and email address for further information.

What does it mean that Aligos Therapeutics (ALGS) is a clinical stage biopharmaceutical company?

Being a clinical stage biopharmaceutical company means Aligos is developing drug candidates currently in clinical development. According to Aligos, it applies a science-driven approach and R&D expertise to advance best-in-class therapies for liver and viral diseases, including chronic HBV infection.